Abstract
Sustained increase in arterial pressure causes left ventricular hypertrophy and adversely affects all myocardial compartments: myocytes, interstitium, and coronary vasculature. Ventricular hypertrophy significantly increases the risk for cardiovascular morbidity and mortality in hypertensive disease. Impairments in coronary circulation and ventricular fibrosis, which are an essential part of hypertensive disease, contribute to that increased risk. This report discusses the mechanisms of hypertension-induced myocardial collagen accumulation and impairments in coronary hemodynamics. Particular attention is given to the interaction of hypertension and aging because aging aggravates hypertensive changes and the incidence of hypertension increases with aging. The effect of therapy on hypertension-induced ventricular fibrosis and impairment in coronary hemodynamics and the risk associated with these changes are also discussed.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Frohlich ED, Apstein C, Chobanian AV, et al.: The heart in hypertension. N Engl J Med 1992, 327:998–1008.
Frohlich ED, Re R: Pathophysiology of systemic arterial hypertension. In Hurst‘s The Heart. Edited by Schlant RC, Alexander RW, O‘Rourke RA, et al. New York: McGraw-Hill; 1998:1635–1650.
Susic D, Frohlich ED: Left ventricular hypertrophy: a pathophysiological and molecular biological perspective. Hypertens Res 1993, 16:163–177.
Frohlich ED: Risk mechanisms in hypertensive heart disease. Hypertension 1999, 34:782–789. A comprehensive, up-to-date review of risk mechanisms in LVH.
Weber KT: The what, why, and how of hypertensive heart disease. J Hum Hypertens 1994, 8:665–675.
Frohlich ED: Left ventricular hypertrophy and sudden death. J Am Coll Cardiol 1998, 32:1460–1462.
Levy D, Garrison RJ, Savage DD, et al.: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322:1561–1566.
Pluim BM, Zwinderman AH, van der Laarse A, et al.: The athlete‘s heart. A meta-analysis of cardiac structure and function. Circulation 2000, 101:336–342.
Whyte GP, Sharma S, George K, et al.: Exercisegas exchange responses in the differentiation of pathologic and physiologic left ventricular hypertrophy. Med Sci Sports Exerc 1999, 31:1237–1241.
Deague JA, Wilson CM, Grigg LE, et al.: Increased left ventricular mass is not associated with impaired left ventricular diastolic filling in normal individuals. J Hypertens 2000, 18:757–762. A study demonstrating that left ventricular mass itself does not correlate with diastolic function.
Zabalgoitia M, Rahman SN, Haley WE, et al.: Comparison in systemic hypertension of left ventricular mass and geometry with systolic and diastolic function in patients < 65 to > or=65 years of age. Am J Cardiol 1998, 82:604–608.
MacLellan WR: Advances in the molecular mechanisms of heart failure. Curr Opin Cardiol 2000, 15:128–135.
Swynghedauw B: Molecular mechanisms of myocardial remodeling. Physiol Rev 1999, 79:215–262. An excellent, very detailed review of molecular mechanisms underlying various forms of heart disease.
Sharov VG, Sabbath HN, Shimoyama H, et al.: Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Am J Pathol 1996, 148:141–149.
Marcus ML, Mueller TM, Eastham CL: Effects of short-and long-term left ventricular hypertrophy on coronary circulation. Am J Physiol 1981, 241:H358-H362.
Nishiyama K, Nishiyama A, Frohlich ED: Regional blood flow in normotensive and hypertensive rats. Am J Physiol 1976, 230:691–698.
Susic D, Nunez E, Hosoya K, et al.: Coronary hemodynamics in aging spontaneously hypertensive and normotensive Wistar-Kyoto rats. J Hypertension 1998, 16:231–237.
Hachamovitch R, Wicker P, Capasso JM, et al.: Alterations of coronary blood flow and reserve with aging in Fischer 344 rats. Am J Physiol 1989, 256:H66-H73.
Cowley AW: Long-term control of arterial blood pressure. Physiol Rev 1992, 72:231–300.
Wicker P, Tarazi RC: Coronary blood flow in left ventricular hypertrophy: a review of experimental data. Eur Heart J 1983, 3(Suppl A):111–118.
Dohi Y, Thiel MA, Buhler FR, et al.: Activation of endothelial L-arginine pathway in resistance arteries. Effect of age and hypertension. Hypertension 1990, 16:170–179.
Treasure CB, Klein JL, Vita JA, et al.: Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 1993, 87:86–93.
Panza JA: Endothelial dysfunction in hypertension. Clin Cardiol 1997, 20(Suppl 2):II26-II33.
Jones CJ, Kuo L, Davis MJ, et al.: Role of nitric oxide in the coronary microvascular responses to adenosine and increased metabolic demand. Circulation 1995, 91:1807–1813.
Ono Y, Ono H, Matsuoka, gnH, et al.: Apoptosis, coronary arterial remodeling, and myocardial infarction after nitric oxide inhibition in SHR. Hypertension 1999, 34:609–616.
Palombo C, Kozakova M, Magagna A, et al.: Early impairment of coronary flow reserve and increase in minimum coronary resistance in borderline hypertensive patients. J Hypertens 2000, 18:453–459. A study demonstrating the involvement of coronary vasculature very early in the course of hypertension.
Hamasaki S, Al Suwaidi J, Higano ST, et al.: Attenuated coronary flow reserve and vascular remodeling in patients with hypertension and left ventricular hypertrophy. J Am Coll Cardiol 2000, 35:1654–1660.
Vatner SF, Hittinger L: Coronary vascular mechanisms involved in decompensation from hypertrophy to heart failure. J Am Coll Cardiol 1993, 22(Suppl A):34A-40A.
Susic D, Varagic J, Frohlich ED: Pharmacologic agents on cardiovascular mass, coronary dynamics and collagen in aged spontaneously hypertensive rats. J Hypertens 1999, 17:1209–1215.
Susic D, Francischetti A, ED Frohlich: Prolonged L-arginine on cardiovascular mass and myocardial hemodynamics and collagen in aged spontaneously hypertensive and normal rats. Hypertension 1999, 33(Part II):451–455.
Kaneko K, Susic D, Nunez E, et al.: Losartan reduces cardiac mass and improves coronary flow reserve in the spontaneously hypertensive rat. J Hypertens 1996, 14:645–653.
Nunez E, Hosoya K, Susic D, et al.: Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Hypertension 1997, 29:519–524.
Motz W, Strauer BE: Improvement of coronary flow reserve after long term therapy with enalapril. Hypertension 1996, 27:1031–1038.
Strauer BE, Schwartzkopf B: Objectives of high blood pressure treatment: left ventricular hypertrophy, diastolic function, and coronary reserve. Am J Hypertens 1998, 11:879–881. A study in hypertensive patients showing an association of left ventricular collagen with diastolic function and coronary flow reserve.
Caspari PG, Newcomb M, Gibson K, et al.: Collagen in the normal and hypertrophied human ventricle. Cardiovasc Res. 1977, 11:554–558.
Weber KT, Sun Y, Guarda E, et al.: Myocardial fibrosis in hypertensive heart disease: an overview of potential regulatory mechanisms. Eur Heart J 1995, 16(Suppl C):24–28.
Rossi MA: Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertension 1998, 16:1031–1041. A study in humans showing a direct correlation between LVH and ventricular fibrosis.
Weber KT: Angiotensin II and connective tissue: homeostasis and reciprocal regulation. Regul Pept 1999, 82:1–17.
Schlaich MP, Schobel HP, Hilgers K, et al.: Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am J Cardiol 2000, 85:1199–2006. A study suggesting a role of aldosterone and salt in the regulation of myocardial collagen concentration in humans.
Yu HCM, Burrell LM, Black MJ, et al.: Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 1998, 98:2621–2628.
Brilla CG, Matsubara LS, Weber KT: Antialdosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Moll Cell Cardiol 1993, 25:563–575.
Sun Y, Ratajska A, Zhou G, et al.: Angiotensin converting enzyme and myocardial fibrosis in rats receiving angiotensin II and aldosterone. J Lab Clin Med 1993, 122:395–403.
Rossi GP, Sacchetto A, Pavan E, et al.: Remodeling of the left ventricle in primary aldosteronism due to Conn‘s adenoma. Circulation 1997, 95:1471–1478.
Re RN: Myocardial hypertrophy, angiotensin, and ACE inhibitors. Angiology 1993, 44:875–881.
Larouche I, Schiffrin EL: Cardiac microvasculature in DOCA-salt hypertensive rats. Effect of endothelin ETA receptor antagonism. Hypertension 1999, 34:795–801.
Horiuchi M, Akishita M, Dzau VJ: Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999, 33:613–621.
Motz W, Schwartzkopff B, Vogt M: Hypertensive heart disease: cardioreparation by reversal of interstitial collagen in patients. Eur Heart J 1995, 16(Suppl C):69–73.
Brilla CG, Matsubara L, Weber KT: Advanced hypertensive heart disease in spontaneously hypertensive rats — lisinopril-mediated regression of myocardial fibrosis. Hypertension 1996, 28:269–275.
Varo N, Etayo JC, Zalba G, et al.: Losartan inhibits the post-transcriptional synthesis of collagen type 1 and reverses left ventricular hypertrophy in spontaneously hypertensive rats. J Hypertens 1999, 17:107–114. A study indicating molecular mechanism of angiotensin II action on collagen synthesis.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Susic, D., Frohlich, E.D. Hypertension and the heart. Curr Hypertens Rep 2, 565–569 (2000). https://doi.org/10.1007/s11906-996-0042-7
Issue Date:
DOI: https://doi.org/10.1007/s11906-996-0042-7